What is EDP Biotech?
Founded in 2005, EDP Biotech Corporation operates as an ISO 13485:2016 certified developer and manufacturer of advanced diagnostic solutions. The company specializes in creating cost-effective, high-precision tools for both human and veterinary applications. Its flagship innovation, ColoPlex, represents a significant advancement in clinical diagnostics, utilizing a multiplex biomarker assay to facilitate the early detection of colorectal cancer. This technology addresses a critical gap in oncology screening, positioning EDP Biotech as a pivotal player in the shift toward proactive, data-driven healthcare outcomes.
The firm's long-term commitment to research and development has allowed it to transition from a research-heavy entity into a commercial-stage manufacturer. By focusing on multiplex biomarker assays, EDP Biotech is effectively scaling its ability to provide actionable medical insights, thereby enhancing patient prognosis through earlier intervention strategies.
How much funding has EDP Biotech raised?
EDP Biotech has raised a total of $76K across 1 funding round:
Debt
$76K
Debt (2021): $76K with participation from PPP
Key Investors in EDP Biotech
PPP
Public-Private Partnership
What's next for EDP Biotech?
With the recent infusion of capital, EDP Biotech is poised to scale its operational capacity and expand the market reach of its diagnostic portfolio. The strategic focus will likely center on broadening the clinical adoption of ColoPlex and potentially diversifying its pipeline to address other high-prevalence conditions. As the company navigates this growth phase, the emphasis will remain on maintaining rigorous quality standards while optimizing manufacturing processes to meet increasing global demand for accessible diagnostic testing. Investors are closely monitoring the firm's ability to translate its technical expertise into sustained market share within the rapidly evolving landscape of molecular diagnostics.
See full EDP Biotech company page
